Chugai to In-license ROS1/TRK Inhibitor Entrectinib

Dear Investor,

Please find attached a press release by Chugai:

https://www.roche.com/180717_Chugai_In_licence_of_Entrectinib.pdf  

Do not hesitate to contact us for any further questions.

With best regards,

Roche Investor Relations
Dr. Karl Mahler Phone: +41 61 68-78503 e-mail: karl.mahler@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Susann Manchado Phone: +41 61-68-75619 e-mail: susann.manchado@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com